Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation

This study will investigate the clinical variables that may be used to predict who among the solid organ transplant recipients will develop cytomegalovirus (CMV) disease after completing antiviral prophylaxis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Transplantation Cytomegalovirus Infections DNA Virus Infections Herpesviridae Infections Infection Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

About this study

This study will investigate the clinical and laboratory variables that may be used to predict who among the solid organ transplant recipients will develop CMV disease after completing antiviral prophylaxis. This is a retrospective study of patients seen at the Mayo Clinic during the past five years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Recipients of liver, kidney, pancreas, heart or lung transplantation

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

Roche Pharma AG

Registry information

Official study title

Clinical Predictors of Late-onset CMV Disease in Solid Organ Transplant Recipients: A Strategy to Improve the Benefits and Reduce the Risks of Anti-CMV Prophylaxis

Important dates

Study start: 2004
Primary completion: 2007
Study completion: 2007
First posted: Sep 15, 2005
Registry last updated: Feb 2, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed